Abstract:Purpose The goal of this study was to assess the safety and tolerability of icotinib hydrochloride (BPI-2009H), a new selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), and to explore its pharmacokinetics (PK) and clinical activity in patients with advanced solid tumors, mainly those with non-small-cell lung cancer (NSCLC) after the failure of the prior platinum-based chemotherapy. Experimental design Different doses of oral icotinib were administered once every 8 h (Q8H) for a 28-continuous-day cycle until disease progression and or undue toxicity was observed. PK studies of subjects’ blood were performed during cycle one (day 1 through 28). Patients aged ≥18 and ≤70 years with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1 and adequate organ functions eligible for the study. Tumor responses were assessed by Response Evaluation Criteria in Solid Tumors (RECIST). K-ras and EGFR mutations in the extracted DNA of fourteen specimens were examined using PCR-based direct sequencing assay. Results Thirty-six patients were enrolled in the study. PK analysis demonstrated that the mean elimination half-life of icotinib was 6 h, and the Tmax was around 2 h. The steady-state concentration of icotinib administered at a dose of 125 mg once every 8 h (Q8H) was significantly higher than that achieved by a dose of 100 mg Q8H. The most frequent treatment-related adverse events (TRAEs) were an acne-like (folliculitis) rash (16/36, 44.4%), diarrhea (8/36, 22.2%) and a decrease in white blood cells (4/36, 11.1%). The maximum-tolerated dose (MTD) was not reached. Among 33 patients with NSCLC, 7 patients exhibited a partial response, 7 showed stable disease at the 24 weeks. Among 14 patients undergoing DNA sequence for K-ras and EGFR mutations, 3 with K-ras mutation presented 2 stable disease (SD) and 1 partial response (PR), 5 with EGFR exon 19 or 21 mutation 2 PR and 3 SD within 4 weeks. Conclusions Oral icotinib was generally well tolerated, with manageable and reversible adverse events (AEs) and showed positive clinical anti-tumor activities in patients with advanced NSCLC. The recommended dose for phase II/III studies with icotinib is 125 mg or 150 mg Q8H.

A Phase I Pharmacokinetics Study of 9-Nitrocamptothecin in Patients with Advanced Solid Tumors.

Research Progress of Status of 9-Nitrocamptothecin

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.

Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo

Preparation of 9-Nitrocamptothecin Liposome and Its Pharmacokinetic after Pulmonary Delivery to Rats

Preparation of 9-Nitrocamptothecin Self-Emulsified Microemulsion and Its Pharmacokinetics in Rats

Self-microemulsifying Drug Delivery System (SMEDDS) Improves Anticancer Effect of Oral 9-Nitrocamptothecin on Human Cancer Xenografts in Nude Mice.

Phase I Study of Icotinib Hydrochloride (BPI-2009H), an Oral EGFR Tyrosine Kinase Inhibitor, in Patients with Advanced NSCLC and Other Solid Tumors

Design and One-Pot Synthesis of New 7-Acyl Camptothecin Derivatives As Potent Cytotoxic Agents

Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.

Potent Antitumor Activity of 10-Methoxy-9-nitrocamptothecin.

Chimmitecan, A Novel 9-Substituted Camptothecin, With Improved Anticancer Pharmacologic Profiles In Vitro And In Vivo

[9-Nitrocamptothecin Nanostructured Lipid Carrier System: in Vitro Releasing Characteristics, Uptake by Cells, and Tissue Distribution in Vivo].

Complex of 9-nitro-camptothecin in hydroxypropyl-β-cyclodextrin: In vitro and in vivo evaluation

Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis.

Advances in Delivery of Irinotecan (CPT-11) Active Metabolite 7-Ethyl-10-hydroxycamptothecin.

A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts

Pharmacokinetics and Urinary Excretion of 9-Nitrocamptothecin Following Intravenous Administration of Lactone and Carboxylate Forms to Rats

Preparation and Antitumor Study of Camptothecin Nanocrystals

Characterization and pharmacodynamic evaluation in vitro of 9-nitro-camptothecin-loaded folate-conjugated polymer micelles as tumor-targeted drug delivery system